Sanara MedTech (SMTI) Q1 2026 earnings review
Pure-Play Transition Delivers Profitability, Though Cash Flow Lags
Sanara MedTech's first full quarter operating strictly as a pure-play surgical company yielded a significant milestone: a return to GAAP profitability from continuing operations ($0.4M, or $0.04 per share). Revenue grew a robust 19% YoY to $27.8M, driven almost entirely by the soft tissue repair portfolio. Management's strategic decision to axe the cash-burning Tissue Health Plus (THP) segment is clearly paying off on the P&L, with gross margins hitting 93% and operating income climbing to $2.6M. However, the balance sheet tells a slightly more complex story: high interest costs and commission payouts resulted in a $2.5M operating cash burn. Full-year revenue guidance was maintained at $116M to $121M.
🐂 Bull Case
Gross margins expanded to 93% from 92% a year ago. Adjusted EBITDA surged 58% YoY to $4.3M. The company is proving that its core surgical business can scale profitably without the drag of the discontinued THP unit.
Soft tissue repair products (CellerateRX, BIASURGE) grew 21% YoY to $24.9M. This momentum persists despite historical Q1 seasonality and a weather-related shipping shutdown in January.
🐻 Bear Case
Sales of bone fusion products contracted 2% YoY to $2.86M. While a smaller part of the business, a decline in this segment contradicts the company's broader growth narrative in the surgical space.
Despite GAAP profitability, Sanara burned $2.5M in operating cash. The company is carrying $46.2M in long-term debt, generating $1.8M in quarterly interest expense, which is severely hampering free cash flow generation.
⚖️ Verdict: 🟢
Bullish. The strategic pivot to a pure-play surgical model has structurally improved the P&L. If management can stabilize the bone fusion segment and manage the debt load, the 93% gross margin profile provides a massive runway for earnings expansion.
Key Themes
The THP Overhang is Officially Gone
Q1 2026 marks the first full quarter where the Tissue Health Plus (THP) segment is fully classified as discontinued operations. Previously, THP was responsible for multimillion-dollar quarterly losses and heavy cash consumption. Shedding this distraction has allowed management to post a clean $0.4M in net income from continuing operations, fundamentally resetting the company's baseline profitability profile.
Soft Tissue Repair Dominates the Top Line
Accelerating demand for CellerateRX Surgical Powder and BIASURGE Advanced Surgical Solution drove soft tissue revenue up 21% YoY to $24.9M. This product category now constitutes roughly 90% of total revenue and is the primary engine behind the 93% gross margin.
Sales Rep and Facility Expansion
The company has expanded its direct sales team to 43 reps and its products are now contracted or approved in over 4,000 hospitals and ambulatory surgery centers (sold into over 1,400 facilities). The independent distributor network also expanded past 450, broadening Sanara's footprint and acting as a multiplier for the direct sales force.
Bone Fusion Segment Reversing
In stark contrast to the thriving soft tissue business, the bone fusion portfolio actually shrank. Sales reversed direction, falling 2% YoY to $2.86M (down from $2.90M in Q1 2025). As Sanara positions itself as a comprehensive surgical supplier, lagging adoption in orthobiologics requires close monitoring.
Operating Cash Burn Persists Despite GAAP Profit
Sanara reported $0.4M in net income but used $2.5M in operating cash. Management attributed the disconnect to timing of commission payouts and higher cash interest expense. With $46.2M in long-term debt costing $1.8M in quarterly interest, the debt burden is masking the underlying cash-generating power of the business operations.
Rising SG&A to Fuel Sales
Selling, general, and administrative expenses climbed 14% YoY to $21.9M. Management noted a $1.9M jump in direct sales and marketing expenses and $0.5M in higher compensation. While currently justified by 19% revenue growth, Sanara must ensure SG&A growth begins decelerating relative to revenue to achieve meaningful net margin expansion.
Macro Impact: Winter Weather Disruption
Management explicitly cited a weather-related shipping interruption in January that caused a three-day shutdown. Factoring in this lost volume, the 19% reported top-line growth is even more impressive and indicates robust underlying hospital demand.
Other KPIs
Stable and slightly accelerating. Improved from 92% in Q1 2025. This exceptional margin profile is a result of favorable product mix shifting further toward the highly profitable soft tissue repair products. This provides significant cushion against the high SG&A spend required to scale the sales force.
Accelerating. Up 58% from $2.7M in the prior year period. Adjusted EBITDA margin improved to 15.5% of revenue, demonstrating that stripping out the non-cash share-based compensation ($1.0M) and heavy interest expense ($1.8M) reveals a highly profitable core operating model.
Guidance
Decelerating. Implies 10% to 14% YoY growth, which is a step down from the 19% growth achieved in Q1 2026. However, it represents sequential growth of 2.5% to 6.1% over Q1.
Stable. The company reaffirmed its full-year outlook, representing 13% to 17% growth over FY 2025's $103.1M. Given Q1's strong 19% performance, the full-year guide implies a slight deceleration in the back half of the year, potentially setting up a low bar to beat.
Key Questions
Bone Fusion Contraction
Sales of bone fusion products contracted 2% this quarter. Is this the result of market share losses, pricing pressure, or a deliberate strategic deprioritization of the segment to focus reps entirely on CellerateRX and BIASURGE?
Debt Refinancing Options
With $46.2 million in debt dragging down cash flows via $1.8M in quarterly interest expense, is management exploring refinancing options to lower the cost of capital now that the core surgical business is GAAP profitable?
Vizient Contract Impact
The Vizient contract for BIASURGE went into effect on January 1. How much of the Q1 soft tissue growth was directly attributable to this new GPO access versus organic growth within existing accounts?